Effect of Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Turkish Deep Vein Thrombotic Patients with and without FV1691 G-A

Akar, Nejat; Yılmaz, Erkan; Akar, Ece; Avcu, Ferit; Yalçin, A.; Cin, Şükrü

doi:10.1016/s0049-3848(99)00164-4

Cited by 48 publications

(47 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 Akar et al stated that PAI-1 46 allele carriers do not have a risk of DVT, but if they have this 46 homozygote with factor V G1691A, the risk increases. 39 Lazo-Langer et al determined that transforming growth factor b1 haplotype production is a risk factor for access thrombosis and that PAI-1 4G/4G genotype adds additional risk (OR = 8.23, 95% CI = 1.47-45.97; p = 0.016). On the other hand, when PAI-1 4G/ 5G was evaluated alone, there was no difference between the case and control groups.…”

Section: Discussionmentioning

confidence: 99%

The Presence of PAI-1 4G/5G and ACE DD Genotypes Increases the Risk of Early-Stage AVF Thrombosis in Hemodialysis Patients

et al. 2011

View full text Add to dashboard Cite

Background: In this study, we investigated the relationship between early arteriovenous fistula (AVF) thrombosis with angiotensin-converting enzyme (ACE) gene and thrombophilic factor gene polymorphisms. Methods: Thirty-five patients who suffered from three or more fistula thrombosis episodes in the early period after AVF operation and 33 control patients with no history of thrombosis for at least 3 years were enrolled in this study. Results: Factor V G1691A Leiden, factor V H1299R (R2), prothrombin G20210A, factor XIIIV34L, b-fibrinogen-455 G-A, glycoprotein IIIa L33P human platelet antigens (HPA-1), methylenetetrahydrofolate reductase C677T, and methylenetetrahydrofolate reductase A1298C gene polymorphisms were similar in both groups (p > 0.05). Plasminogen activator inhibitor 1 (PAI-1) 4G/5G genotype in the study group and 4G/4G genotype in the control group were significantly higher (p = 0.014). No significant difference was detected in terms of the 5G/5G genotype. With regard to the ACE gene polymorphism, the control group showed more ID genotype (19/33, 57.6%), whereas the study group showed more DD genotype (17/35, 48.6%). II genotype was similar in both groups (x 2 = 7.40, p = 0.025). The rate of ACE inhibitor-angiotensin II receptor blockers use was 5/35 in the study group (14.3%) and 5/33 in the control group (15.2%). Individuals with PAI-1 4G/5G genotype showed 5.03 times more risk of thrombosis when compared with 4G/4G and 5G/5G genotypes [p = 0.008, OR = 5.03, 95% confidence interval (1.44:17.64)]. Individuals with ACE DD genotype showed 4.25 times more risk of thrombosis when compared with II and ID [p = 0.008, OR = 4.25, 95% confidence interval (1.404:12.83)]. Conclusion: PAI-1 4G/5G and ACE DD genotypes are associated with increased risk for early AVF thrombosis.

show abstract

Section: Discussionmentioning

confidence: 99%

The Presence of PAI-1 4G/5G and ACE DD Genotypes Increases the Risk of Early-Stage AVF Thrombosis in Hemodialysis Patients

et al. 2011

View full text Add to dashboard Cite

show abstract

“…One study found an increased odds ratio of 5.5x for DVT with the 4G allele, increased even greater when combined with concurrent Factor V Leiden. 37 A second study found an 8.14ϫ increased risk elevation in patients with the 4G allele combined with other thrombophilic markers, 38 whereas PE was increased in 4G/4G patients with protein S deficiency (odds ratio 4.5ϫ). 39 The degradation of fibrin polymers by plasmin ultimately results in the creation of fragment E and 2 molecules of fragment D which, during physiological thrombolysis, are released as a covalently linked dimer (d-dimer).…”

Section: Plasminogen Activators and Thrombosismentioning

confidence: 97%

Mechanisms of Venous Thrombosis and Resolution

Wakefield

Myers

Henke

2008

ATVB

327

275

View full text Add to dashboard Cite

Abstract-Venous thromboembolism is a significant health care problem in the US. In this review, the unique role of inflammation to the venous thrombotic process is emphasized as well as the potential role of abnormalities of fibrinolytic mechanisms to the thrombotic process. Inflammation influences not only thrombogenesis but also thrombus resolution and vein wall remodeling, and these interactions are also discussed. Knowledge of molecular and immunologic mechanisms for venous thrombosis and its resolution should allow for the future development of targeted therapies.

show abstract

“…16 The primers used and the conditions for polymerase chain reaction (PCR) analysis were as described previously. [12][13][14][15][16][17][18][19][20][21][22] Polymerase chain reaction of the exon 10 of the FV gene was performed according to the previously described method. Amplified DNA was digested with HindIII enzyme (Promega, Madison, Wisconsin) at 37 C and subjected to 2% agarose gel electrophoresis.…”

Section: Gel Analysis and Genotypingmentioning

confidence: 99%

“…We felt it was prudent to study genetic risk factors for VTE in Turkish population as limited information exists on this subject. [12][13][14][15] The objective of our study was to evaluate and confirm the relationship between the factor V, PT, MTHFR mutations, plasminogen activator inhibitor 1 (PAI-1 -675) polymorphisms, and PE and PE þ DVT phenotype in Turkish population.…”

Section: Introductionmentioning

confidence: 99%

Genetic Mutations in Turkish Population With Pulmonary Embolism and Deep Venous Thrombosis

Küpeli̇

Verdı

Simsek

et al. 2010

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a universal health hazard. Inherited and acquired risk factors increase the risk of VTE. We evaluated the relationship between factor V (G1691A, A1090G, and A1299G), prothrombin (PT G20210A), methylenetetrahydrofolate reductase (MTHFR C677T) mutations, plasminogen activator inhibitor 1 (PAI-1 -675) polymorphism, and VTE in Turkish population. In all, 80 patients with VTE and 104 controls were included. Heterozygous factor V Leiden (FVL) mutation was significantly higher among patients (P = .04) with allele frequency of 6.3% (P = .01). Heterozygous PT G20210A mutation was also significantly higher among patients (P = .001) with allele frequency of 6.9% (P = .003). MTHFR 677TT genotype was significantly higher in patients (P = .009) with allele frequency of 23.8% (P = .005). No significant difference was found in FV A1090G and FV A1299G mutation rate as well as PAI-1 genotypes and their allele frequencies (P > .05). Thus, frequencies of FV G1691A, PT G20210A, and MTHFR C677T mutations are higher in patients with VTE. FV A1090G, FV A1299G mutations, and PAI-1 gene polymorphisms may not be a risk factor for VTE in Turkish population.

show abstract

Effect of Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Turkish Deep Vein Thrombotic Patients with and without FV1691 G-A

Cited by 48 publications

References 10 publications

The Presence of PAI-1 4G/5G and ACE DD Genotypes Increases the Risk of Early-Stage AVF Thrombosis in Hemodialysis Patients

The Presence of PAI-1 4G/5G and ACE DD Genotypes Increases the Risk of Early-Stage AVF Thrombosis in Hemodialysis Patients

Mechanisms of Venous Thrombosis and Resolution

Genetic Mutations in Turkish Population With Pulmonary Embolism and Deep Venous Thrombosis

Contact Info

Product

Resources

About